Gene therapy in the CNS

被引:100
作者
Costantini, LC
Bakowska, JC
Breakefield, XO
Isacson, O
机构
[1] Massachusetts Gen Hosp E, Dept Mol Neurogenet, Charlestown, MA 02129 USA
[2] Harvard Univ, McLean Hosp, Sch Med, Neuroregenerat Lab, Belmont, MA 02178 USA
[3] Harvard Univ, Sch Med, Dept Neurol, Boston, MA USA
[4] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA
关键词
vector; Parkinson's disease; Huntington's disease; ischemia; brain tumor; lysosomal storage disease;
D O I
10.1038/sj.gt.3301119
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gene therapy for neurological disorder is currently an experimental concept. The goals for clinical utilization are the relief of symptoms, slowing of disease progression, and correction of genetic abnormalities. Experimental studies are realizing these goals in the development of gene therapies in animal models. Discoveries of the molecular basis of neurological disease and advances in gene transfer systems have allowed focal and global delivery of therapeutic genes for a wide variety of CNS disorders. Limitations are still apparent, such as stability and regulation of transgene expression, and safety of both vector and expressed transgene. In addition, the brain adds several challenges not seen in peripheral gene therapy paradigms, such as post-mitotic cells, heterogeneity of cell types and circuits, and limited access. Moreover, ii is likely that several modes of gene delivery will be necessary for successful gene therapies of the CNS. Collaborative efforts between clinicians and basic researchers will likely yield effective gene therapy in the CNS.
引用
收藏
页码:93 / 109
页数:17
相关论文
共 245 条
[1]  
ABOODY KS, UNPUB NEW PLATFORM G
[2]   Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients [J].
Aebischer, P ;
Schluep, M ;
Deglon, N ;
Joseph, JM ;
Hirt, L ;
Heyd, B ;
Goddard, M ;
Hammang, JP ;
Zurn, AD ;
Kato, AC ;
Regli, F ;
Baetge, EE .
NATURE MEDICINE, 1996, 2 (06) :696-699
[3]   Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies [J].
Aghi, M ;
Kramm, CM ;
Chou, TC ;
Breakefield, XO ;
Chiocca, EA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (05) :370-380
[4]   Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET [J].
Andrews, TC ;
Brooks, DJ .
MOLECULAR MEDICINE TODAY, 1998, 4 (12) :532-539
[5]   E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors [J].
Armentano, D ;
Smith, MP ;
Sookdeo, CC ;
Zabner, J ;
Perricone, MA ;
St George, JA ;
Wadsworth, SC ;
Gregory, RJ .
JOURNAL OF VIROLOGY, 1999, 73 (08) :7031-7034
[6]   Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy [J].
Aronsohn, AI ;
Hughes, JA .
JOURNAL OF DRUG TARGETING, 1998, 5 (03) :163-169
[7]  
Balague C, 1997, J VIROL, V71, P3299
[8]   Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease [J].
Bankiewicz, KS ;
Leff, SE ;
Nagy, D ;
Jungles, S ;
Rokovich, J ;
Spratt, K ;
Cohen, L ;
Libonati, M ;
Snyder, RO ;
Mandel, RJ .
EXPERIMENTAL NEUROLOGY, 1997, 144 (01) :147-156
[9]   Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7 [J].
Barnett, FH ;
Rainov, NG ;
Ikeda, K ;
Schuback, DE ;
Elliott, P ;
Kramm, CM ;
Chase, M ;
Qureshi, NH ;
Harsh, G ;
Chiocca, EA ;
Breakefield, XO .
CANCER GENE THERAPY, 1999, 6 (01) :14-20
[10]   Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′γ)2 antibody [J].
Bartlett, JS ;
Kleinschmidt, J ;
Boucher, RC ;
Samulski, RJ .
NATURE BIOTECHNOLOGY, 1999, 17 (02) :181-186